By Rishika Sadam
Feb 16 (Reuters) – Biocon is aiming for high-double-digit percentage revenue growth as the Indian pharmaceutical firm prepares to launch generic versions of weight-loss drugs globally even as it remains cautious about an early rollout in the home market, a top company executive told Reuters.
The company is counting on demand for obesity medicines as it expands a pipeline that includes copycat versions of Novo Nordisk’s Wegovy, whose patent for semaglutide in a few markets expires in 2026.
Indian drugmakers, including Dr Reddy’s, Lupin, Sun Pharmaceutical and at least half a dozen others are racing to bring cheaper copies to markets once the active compound goes off patent.
Bengaluru-based Biocon is targeting a U.S. launch of generic liraglutide in the first quarter of the next financial year, CEO Siddharth Mittal said in an interview on Friday. Liraglutide is also used for obesity treatment.
It aims to launch generic Wegovy in Canada next year, subject to regulatory approval, Mittal said. It is also planning launches over the next few years in India, Brazil, Mexico, Turkey, and parts of the Middle East and Latin America.
The company, however, is cautious about an early start in India due to fierce price competition and local clinical trial requirements, Mittal said.
“There’s going to be fierce competition in India,” Mittal said, citing low price expectations. He said Biocon is exploring approval in a specific overseas market first, which could help it seek a clinical trial waiver in India under local rules.
In India, Biocon would need to run a late-stage clinical trial before launch. The company is weighing whether that cost would be justified, Mittal said, or whether it should seek a waiver.
The obesity medicines market, according to several forecasts, is expected to reach at least $150 billion globally by the early 2030s, and analysts expect generic versions to be priced at least 60% below the originator products.
Biocon expects high double-digit percentage revenue growth, Mittal said. The company’s annual revenue grew 5.4% in fiscal 2025 from a year ago, but it has been growing in early double-digits on a quarter-on-quarter basis.
India is not Biocon’s main market. The company derives significant share of revenue from the United States and parts of Europe.
(Reporting by Rishika Sadam; Editing by Tasim Zahid)
Comments